bispecifics & car-t therapy in dlbcl: sequencing and selecting between these agents
Published 1 year ago • 127 plays • Length 1:04Download video MP4
Download video MP3
Similar videos
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
2:52
comparing the efficacy and curative potential of car-t therapy & bispecific antibodies in r/r dlbcl
-
2:38
weighing up the pros and cons of car-t therapy and bispecific antibodies in r/r dlbcl
-
4:14
choosing the right car-t therapy for r/r dlbcl
-
2:52
current immunotherapeutic approaches in dlbcl: the value of car-t cells and bispecific antibodies
-
1:44
bispecific antibodies vs car-t cells in dlbcl: the benefit of car-t therapy
-
4:10
the use of adcs & bispecific antibodies before and after car-t therapy in third-line dlbcl
-
2:10
new algorithm for second-line dlbcl: the role of car-t therapy
-
6:54
the future of car-t therapy in the management of dlbcl
-
0:44
emerging options for patients with dlbcl who relapse after car-t therapy
-
1:23
advantages of bispecific antibodies over car-t therapy in lbcl
-
3:12
the role of car t-cell therapy in dlbcl
-
2:34
car-t & bispecific antibodies in second-line dlbcl
-
1:19
contemporary approaches to the management of r/r dlbcl
-
2:05
strategies to implement car-t in dlbcl
-
3:55
managing relapse post-car-t therapy in dlbcl & the need to change clinical trial inclusion criteria
-
2:42
clinical indications for car-t therapy in dlbcl & the possibility of moving car-t into earlier lines
-
1:14
the car t-cell strategy vs bispecific antibodies
-
3:21
safety management of car-t cell therapy in dlbcl